高强度聚焦超声治疗晚期前列腺癌对患者生存及免疫状态的影响

Objective To investigate the influence of high intensity focused ultrasound(HIFU) treatment on survival and immune state of patients as local therapy for advanced prostate cancer following hormonal therapy. Methods Between March 2000 and December 2010, we performed a prospective, controlled, and nonrandomized study on 64 patients with advanced PCa after hormonal therapy. Control group (30 cases) received hormonal therapy alone, and HIFU group (34 cases) received HIFU treatment following hormonal therapy. To make survival analyses by the method of Kaplan-Meier survival curves and calculating survival rates. Some patients were detected the immunity index of peripheral blood before and after treatment, including IL-2, IFN-γ, VEGF, TGF-β1 and CD4+CD25+Foxp3+ cell. Results The 3-year and 5-year survival rates of HIFU group were 76.92% and 51.26%, and those of control group were 45.19% and 25.83%. There was significant difference between two groups in survival curve (P=0.0404). Compared with control group, IL-2 (P = 0.042) and IFN-γ (P = 0.019) level of peripheral blood in HIFU group significantly rose, and VEGF (P = 0.032), TGF-β1(P = 0.042) level and CD4+CD25+Foxp3+ (%)(P = 0.001) significantly decreased. Conclusion After hormonal therapy, utilizing HIFU to strengthen local control of advanced prostate cancer not only significantly prolonged the survival time of patients, but also improved systemic immune state.